Table 2 Studies reporting exact numbers, odds ratios, or relative risks for various birth outcomes in women with IBD exposed to TNF-α blockers compared with unexposed controls with IBD
From: Safety of TNF-α inhibitors during IBD pregnancy: a systematic review
Author | Patients with IBD exposed to TNF-α blockers | Controls | Spontaneous abortions or stillbirths | Preterm delivery | Low birth weight | Abnormalities/major birth defects/malformations | Infections during the first 12 months of life |
|---|---|---|---|---|---|---|---|
Johnson et al. [72] | 34a | 55b | 5/34 versus 3/55; OR 2.99 (95% CI 0.67 to 13.41) | − | − | 2/34 versus 2/53; OR 1.59 (0.21 to 11.9) | − |
Schnitzler et al. [54] | 42 | 78 | 9/42 versus 12/78; OR 1.5 (0.57 to 3.92) | 8/32 versus 8/65; OR 2.38 (0.80 to 7.06) | 6/32 versus 9/65; OR 1.44 (0.46 to 4.46) | 1/42 versus 1/78; OR 1.87 (0.11 to 30.8) | − |
Casanova et al. [48] | 202c | 110 | 20/202 versus 19/110; OR 0.53 (0.27 to 1.04) | 8/202 versus 13/110; OR 0.31 (0.12 to 0.77) | 12/202 versus 11/110; OR 0.57 (0.24 to 1.33) | 2/202 versus 0/110; (no OR or CI) | − |
Mahadevan et al. [51] | 79c | 291/326 | RR 1.29 (0.79 to 2.11); Biologics alone:; RR 2.56 (1.07 to 4.12) | RR 1.83 (1.01 to 3.31); Biologics alone:; RR 0.89 (0.54 to 1.47) | − | − | RR 1.35 (1.01-1.80); Biologics alone:; RR 0.89 (0.70-1.12) |